Generation and characterization of human anti-human IL-21 neutralizing monoclonal antibodies

mAbs

Volumn 4, Issue 1, 2012, Pages 69-83

  Maurer, Mark F ^a   Garrigues, Ursula ^a   Jaspers, Stephen R ^a,b   Meengs, Brent ^a   Rixon, Mark W ^a   Stevens, Brenda L ^a   Lewis, Kenneth B ^a,c   Julien, Susan H ^a   Bukowski, Thomas R ^a,d   Wolf, Anitra C ^a,e   Hamacher, Nels B ^a   Snavely, Mark ^a   Dillon, Stacey R ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b REGENERON PHARMACEUTICALS INC   (United States)

^c CMC Biologics   (United States)

^d Immune Design   (United States)

^e NOVO NORDISK INC   (United States)

Author keywords

Autoimmunity; Human Ig transgenic mice; IL 21; Interleukin 21; mAb

Indexed keywords

HUMAN IMMUNOGLOBULIN; HUMAN INTERLEUKIN 21 BINDING MONOCLONAL ANTIBODY; HUMAN INTERLEUKIN 21 NEUTRALIZING MONOCLONAL ANTIBODY; INTERLEUKIN 21; INTERLEUKIN 21 RECEPTOR; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; RECOMBINANT INTERLEUKIN 21; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BIOASSAY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNIZATION; INHIBITION KINETICS; MALE; MOLECULAR CLONING; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRE B LYMPHOCYTE; SURFACE PLASMON RESONANCE; TRANSGENIC MOUSE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; AUTOIMMUNITY; B-LYMPHOCYTES; CELL LINE; CHO CELLS; CRICETINAE; EPITOPES; HUMANS; INTERLEUKINS; KILLER CELLS, NATURAL; MICE; MICE, TRANSGENIC; PRECURSOR CELLS, B-LYMPHOID; RABBITS; RATS; RECEPTORS, INTERLEUKIN-21; T-LYMPHOCYTES;

EID: 84856790983     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.4.1.18713     Document Type: Article

References (66)

1. Monteleone G, Pallone F, Macdonald TT. Interleukin-21 (IL-21)-mediated pathways in T cell-mediated disease. Cytokine Growth Factor Rev 2009; 20:185-91; PMID:19261537; http://dx.doi.org/10.1016/j.cytogfr.2009.02.002.
2. Ettinger R, Kuchen S, Lipsky PE. Interleukin 21 as a target of intervention in autoimmune disease. Ann Rheum Dis 2008; 67:83-6; PMID:19022821; http://dx.doi.org/10.1136/ard.2008.098400.
3. Leonard WJ, Zeng R, Spolski R. Interleukin 21: a cytokine/cytokine receptor system that has come of age. J Leukoc Biol 2008; 84:348-56; PMID:18467657; http://dx.doi.org/10.1189/jlb.0308149.
4. Monteleone G, Caruso R, Fina D, Peluso I, Gioia V, Stolfi C, et al. Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21. Gut 2006; 55:1774-80; PMID:16682426; http://dx.doi.org/10. 1136/gut.2006.093187.
5. Distler JH, Jüngel A, Kowal-Bielecka O, Michel BA, Gay RE, Sprott H, et al. Expression of interleukin- 21 receptor in epidermis from patients with systemic sclerosis. Arthritis Rheum 2005; 52:856-64; PMID:15751077; http://dx.doi.org/10.1002/art.20883.
6. Jüngel A, Distler JH, Kurowska-Stolarska M, Seemayer CA, Seibl R, Forster A, et al. Expression of interleukin- 21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritis. Arthritis Rheum 2004; 50:1468-76; PMID:15146416; http://dx.doi.org/10.1002/art.20218.
7. Li J, Shen W, Kong K, Liu Z. Interleukin-21 induces T-cell activation and proinflammatory cytokine secretion in rheumatoid arthritis. Scand J Immunol 2006; 64:515-22; PMID:17032244; http://dx.doi.org/10.1111/j.1365-3083.2006. 01795.x.
8. Caruso R, Fina D, Peluso I, Fantini MC, Tosti C, Del Vecchio Blanco G, et al. IL-21 is highly produced in Helicobacter pylori-infected gastric mucosa and promotes gelatinases synthesis. J Immunol 2007; 178:5957-65; PMID:17442980.
9. Caruso R, Fina D, Peluso I, Stolfi C, Fantini MC, Gioia V, et al. A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant, MIP-3alpha, by gut epithelial cells. Gastroenterology 2007; 132:166-75; PMID:17241869; http://dx.doi.org/10.1053/j.gastro.2006.09.053.
10. Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, Gross JA, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000; 408:57-63; PMID:11081504; http://dx.doi.org/10.1038/35040504.
11. Korn T, Bettelli E, Gao W, Awasthi A, Jäger A, Strom TB, et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007; 448:484-7; PMID:17581588; http://dx.doi.org/10.1038/nature05970.
12. Nurieva R, Yang XO, Martinez G, Zhang Y, Panopoulos AD, Ma L, et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007; 448:480-3; PMID:17581589; http://dx.doi.org/10.1038/ nature05969.
13. Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Egawa T, et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007; 8:967-74; PMID:17581537; http://dx.doi.org/10.1038/ni1488.
14. + T cell-B cell collaboration. J Immunol 2007; 179:5886-96; PMID:17947662.
15. Vogelzang A, McGuire HM, Yu D, Sprent J, Mackay CR, King C. A fundamental role for interleukin-21 in the generation of T follicular helper cells. Immunity 2008; 29:127-37; PMID:18602282; http://dx.doi.org/10.1016/j.immuni. 2008.06.001.
16. Spolski R, Leonard WJ. IL-21 and T follicular helper cells. Int Immunol 2010; 22:7-12; PMID:19933709; http://dx.doi.org/10.1093/intimm/dxp112.
17. Fuqua CF, Akomeah R, Price JO, Adunyah SE. Involvement of ERK-1/2 in IL-21-induced cytokine production in leukemia cells and human monocytes. Cytokine 2008; 44:101-7; PMID:18707899; http://dx.doi.org/10.1016/j.cyto.2008. 06.010.
18. + T cells. Cell Immunol 2011; 267:102-8; PMID:21227406; http://dx.doi.org/10.1016/j.cellimm. 2010.12.003.
19. Brandt K, Bulfone-Paus S, Foster DC, Rückert R. Interleukin-21 inhibits dendritic cell activation and maturation. Blood 2003; 102:4090-8; PMID:12893770; http://dx.doi.org/10.1182/blood-2003-03-0669.
20. Brandt K, Bulfone-Paus S, Jenckel A, Foster DC, Paus R, Rückert R. Interleukin-21 inhibits dendritic cell-mediated T cell activation and induction of contact hypersensitivity in vivo. J Invest Dermatol 2003; 121:1379-82; PMID:14675186; http://dx.doi.org/10.1046/j.1523-747.2003.12603.x.
21. Ettinger R, Kuchen S, Lipsky PE. The role of IL-21 in regulating B-cell function in health and disease. Immunol Rev 2008; 223:60-86; PMID:18613830; http://dx.doi.org/10.1111/j.1600-065X.2008.00631.x.
22. Rasmussen TK, Andersen T, Hvid M, Hetland ML, Hørslev-Petersen K, Stengaard-Pedersen K, et al. Increased interleukin 21 (IL-21) and IL-23 are associated with increased disease activity and with radio-graphic status in patients with early rheumatoid arthritis. J Rheumatol 2010; 37:2014-20; PMID:20682664; http://dx.doi.org/10.3899/jrheum.100259.
23. Niu X, He D, Zhang X, Yue T, Li N, Zhang JZ, et al. IL-21 regulates Th17 cells in rheumatoid arthritis. Hum Immunol 2010; 71:334-41; PMID:20079789; http://dx.doi.org/10.1016/j.humimm.2010.01.010.
24. Li J, Pan HF, Cen H, Tian J, Ma Y, Tao JH, et al. Interleukin-21 as a potential therapeutic target for systemic lupus erythematosus. Mol Biol Rep 2011; 38:4077-81; PMID:21107711; http://dx.doi.org/10.1007/s11033-010-0527-y.
25. Yuan FL, Hu W, Lu WG, Li X, Li JP, Xu RS, et al. Targeting interleukin-21 in rheumatoid arthritis. Mol Biol Rep 2011; 38:1717-21; PMID:20848219; http://dx.doi.org/10.1007/s11033-010-0285-x.
26. Monteleone G, Monteleone I, Fina D, Vavassori P, Del Vecchio Blanco G, Caruso R, et al. Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease. Gastroenterology 2005; 128:687-94; PMID:15765404; http://dx.doi.org/10.1053/j.gastro.2004.12.042.
27. Fina D, Caruso R, Pallone F, Monteleone G. Interleukin-21 (IL-21) controls inflammatory pathways in the gut. Endocr Metab Immune Disord Drug Targets 2007; 7:288-91; PMID:18220949; http://dx.doi.org/10.2174/ 187153007782794308.
28. Caprioli F, Sarra M, Caruso R, Stolfi C, Fina D, Sica G, et al. Autocrine regulation of IL-21 production in human T lymphocytes. J Immunol 2008; 180:1800-7; PMID:18209077.
29. Caruso R, Costanzo A, Monteleone G. Pathogenic role of interleukin-21 in psoriasis. Cell Cycle 2009; 8:3629-30; PMID:19884801; http://dx.doi.org/10.4161/ cc.8.22.9964.
30. Asano K, Ikegami H, Fujisawa T, Nishino M, Nojima K, Kawabata Y, et al. Molecular scanning of interleukin-21 gene and genetic susceptibility to type 1 diabetes. Hum Immunol 2007; 68:384-91; PMID:17462506; http://dx.doi.org/10.1016/ j.humimm.2007.01.009.
31. van Heel DA, Franke L, Hunt KA, Gwilliam R, Zhernakova A, Inouye M, et al. A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. Nat Genet 2007; 39:827-9; PMID:17558408; http://dx.doi.org/10.1038/ng2058.
32. Sawalha AH, Kaufman KM, Kelly JA, Adler AJ, Aberle T, Kilpatrick J, et al. Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus. Ann Rheum Dis 2008; 67:458-61; PMID:17720724; http://dx.doi.org/10.1136/ard.2007.075424.
33. Liu Y, Helms C, Liao W, Zaba LC, Duan S, Gardner J, et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet 2008; 4:1000041; PMID:18369459; http://dx.doi.org/10.1371/ journal.pgen.1000041.
34. Chatterjee R, Batra J, Ghosh B. A common exonic variant of interleukin21 confers susceptibility to atopic asthma. Int Arch Allergy Immunol 2009; 148:137-46; PMID:18802358; http://dx.doi.org/10.1159/000155744.
35. Festen EA, Goyette P, Scott R, Annese V, Zhernakova A, Lian J, et al. Genetic variants in the region harbouring IL2/IL21 associated with ulcerative colitis. Gut 2009; 58:799-804; PMID:19201773; http://dx.doi.org/10.1136/gut. 2008.166918.
36. Daha NA, Kurreeman FA, Marques RB, Stoeken-Rijsbergen G, Verduijn W, Huizinga TW, et al. Confirmation of STAT4, IL2/IL21 and CTLA4 polymorphisms in rheumatoid arthritis. Arthritis Rheum 2009; 60:1255-60; PMID:19404967; http://dx.doi.org/10.1002/art.24503.
37. Glas J, Stallhofer J, Ripke S, Wetzke M, Pfennig S, Klein W, et al. Novel genetic risk markers for ulcerative colitis in the IL2/IL21 region are in epistasis with IL23R and suggest a common genetic background for ulcerative colitis and celiac disease. Am J Gastroenterol 2009; 104:1737-44; PMID:19455118; http://dx.doi.org/10.1038/ajg.2009.163.
38. Márquez A, Orozco G, Martínez A, Palomino-Morales R, Fernández-Arquero M, Mendoza JL, et al. Novel association of the interleukin 2-interleukin 21 region with inflammatory bowel disease. Am J Gastroenterol 2009; 104:1968-75; PMID:19471255; http://dx.doi.org/10.1038/ajg. 2009.224.
39. Webb R, Merrill JT, Kelly JA, Sestak A, Kaufman KM, Langefeld CD, et al. A polymorphism within IL21R confers risk for systemic lupus erythematosus. Arthritis Rheum 2009; 60:2402-7; PMID:19644854; http://dx.doi.org/10.1002/art. 24658.
40. Coenen MJ, Trynka G, Heskamp S, Franke B, van Diemen CC, Smolonska J, et al. Common and different genetic background for rheumatoid arthritis and coeliac disease. Hum Mol Genet 2009; 18:4195-203; PMID:19648290; http://dx.doi.org/10. 1093/hmg/ddp365.
41. Guo Y, Zhang LS, Yang TL, Tian Q, Xiong DH, Pei YF, et al. IL21R and PTH may underlie variation of femoral neck bone mineral density as revealed by a genome-wide association study. J Bone Miner Res 2010; 25:1042-8; PMID:19874204.
42. Hinks A, Eyre S, Ke X, Barton A, Martin P, Flynn E, et al. Childhood Arthritis Prospective Study; UKRAG Consortium; BSPAR Study Group. Association of the AFF3 gene and IL2/IL21 gene region with juvenile idiopathic arthritis. Genes Immun 2010; 11:194-8; PMID:20072139; http://dx.doi.org/10.1038/gene.2009. 105.
43. Nohra R, Beyeen AD, Guo JP, Khademi M, Sundqvist E, Hedreul MT, et al. RGMA and IL21R show association with experimental inflammation and multiple sclerosis. Genes Immun 2010; 11:279-93; PMID:20072140; http://dx.doi.org/10. 1038/gene.2009.111.
44. Maiti AK, Kim-Howard X, Viswanathan P, Guillén L, Rojas-Villarraga A, Deshmukh H, et al. Confirmation of an association between rs6822844 at the Il2-Il21 region and multiple autoimmune diseases: evidence of a general susceptibility locus. Arthritis Rheum 2010; 62:323-9; PMID:20112382; http://dx.doi.org/10.1002/art.27222.
45. Hollis-Moffatt JE, Gearry RB, Barclay ML, Merriman TR, Roberts RL. Consolidation of evidence for association of the KIAA1109-TENR-IL2-IL21 rs6822844 variant with Crohn's disease. Am J Gastroenterol 2010; 105:1204-5; PMID:20445516; http://dx.doi.org/10.1038/ajg.2010.34.
46. Petukhova L, Duvic M, Hordinsky M, Norris D, Price V, Shimomura Y, et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature 2010; 466:113-7; PMID:20596022; http://dx.doi.org/10. 1038/nature09114.
47. Warren RB, Smith RL, Flynn E, Bowes J, Eyre S, Worthington J, UKRAG Consortium. A systematic investigation of confirmed autoimmune loci in early-onset psoriasis reveals an association with IL2/IL21. Br J Dermatol 2011; 164:660-4; PMID:21375519.
48. Sarra M, Franzè E, Pallone F, Monteleone G. Targeting interleukin-21 in inflammatory diseases. Expert Opin Ther Targets 2011; 15:695-702; PMID:21391901; http://dx.doi.org/10.1517/14728222.2011.561319.
49. Vugmeyster Y, Guay H, Szklut P, Qian MD, Jin M, Widom A, et al. In vitro potency, pharmacokinetic profiles and pharmacological activity of optimized anti-IL-21R antibodies in a mouse model of lupus. MAbs 2010; 2:335-46; PMID:20424514; http://dx.doi.org/10.4161/mabs.2.3.11850.
50. Vugmeyster Y, Allen S, Szklut P, Bree A, Ryan M, Ma M, et al. Correlation of pharmacodynamic activity, pharmacokinetics and anti-product antibody responses to anti-IL-21R antibody therapeutics following IV administration to cynomolgus monkeys. J Transl Med 2010; 8:41; PMID:20420683; http://dx.doi.org/ 10.1186/1479-5876-8-41.
51. Herber D, Brown TP, Liang S, Young DA, Collins M, Dunussi-Joannopoulos K. IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression. J Immunol 2007; 178:3822-30; PMID:17339481.
52. Zhang JL, Foster D, Sebald W. Human IL-21 and IL-4 bind to partially overlapping epitopes of common gamma-chain. Biochem Biophys Res Commun 2003; 300:291-6; PMID:12504082; http://dx.doi.org/10.1016/S0006-291X(02)02836-X.
53. Gross JA, Dillon SR, Mudri S, Johnston J, Littau A, Roque R, et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. Immunity 2001; 15:289-302; PMID:11520463; http://dx.doi.org/10.1016/S1074-7613(01)00183-2.
54. Asao H, Okuyama C, Kumaki S, Ishii N, Tsuchiya S, Foster D, et al. Cutting edge: the common gamma-chain is an indispensable subunit of the IL-21 receptor complex. J Immunol 2001; 167:1-5; PMID:11418623.
55. Habib T, Senadheera S, Weinberg K, Kaushansky K. The common gamma chain (gammac) is a required signaling component of the IL-21 receptor and supports IL-21-induced cell proliferation via JAK3. Biochemistry 2002; 41:8725-31; PMID:12093291; http://dx.doi.org/10.1021/bi0202023.
56. Ettinger R, Sims GP, Fairhurst AM, Robbins R, da Silva YS, Spolski R, et al. IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells. J Immunol 2005; 175:7867-79; PMID:16339522.
57. Bondensgaard K, Breinholt J, Madsen D, Omkvist DH, Kang L, Worsaae A, et al. The existence of multiple conformers of interleukin-21 directs engineering of a superpotent analogue. J Biol Chem 2007; 282:23326-36; PMID:17565991; http://dx.doi.org/10.1074/jbc.M701313200.
58. Kang L, Bondensgaard K, Li T, Hartmann R, Hjorth SA. Rational design of interleukin-21 antagonist through selective elimination of the gammaC binding epitope. J Biol Chem 2010; 285:12223-31; PMID:20167599; http://dx.doi.org/10. 1074/jbc.M110.101444.
59. Young DA, Hegen M, Ma HL, Whitters MJ, Albert LM, Lowe L, et al. Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum 2007; 56:1152-63; PMID:17393408; http://dx.doi.org/10.1002/art.22452.
60. Bubier JA, Bennett SM, Sproule TJ, Lyons BL, Olland S, Young DA, et al. Treatment of BXSB-Yaa mice with IL-21R-Fc fusion protein minimally attenuates systemic lupus erythematosus. Ann NY Acad Sci 2007; 1110:590-601; PMID:17911475; http://dx.doi.org/10.1196/annals.1423.063.
61. Fina D, Sarra M, Fantini MC, Rizzo A, Caruso R, Caprioli F, et al. Regulation of gut inflammation and th17 cell response by interleukin-21. Gastroenterology 2008; 134:1038-48; PMID:18395085; http://dx.doi.org/10.1053/j. gastro.2008.01.041.
62. Caruso R, Botti E, Sarra M, Esposito M, Stolfi C, Diluvio L, et al. Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat Med 2009; 15:1013-5; PMID:19684581; http://dx.doi.org/10.1038/nm.1995.
63. Bucher C, Koch L, Vogtenhuber C, Goren E, Munger M, Panoskaltsis-Mortari A, et al. IL-21 blockade reduces graft-versus-host disease mortality by supporting inducible T regulatory cell generation. Blood 2009; 114:5375-84; PMID:19843883; http://dx.doi.org/10.1182/blood-2009-05-221135.
64. McGuire HM, Walters S, Vogelzang A, Lee CM, Webster KE, Sprent J, et al. Interleukin-21 is critically required in autoimmune and allogeneic responses to islet tissue in murine models. Diabetes 2011; 60:867-75; PMID:21357471; http://dx.doi.org/10.2337/db10-1157.
65. Horton RM, Hunt HD, Ho SN, Pullen JK, Pease LR. Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. Gene 1989; 77:61-8; PMID:2744488; http://dx.doi.org/10.1016/0378-1119(89)90359-4.
66. Hippen KL, Bucher C, Schirm DK, Bearl AM, Brender T, Mink KA, et al. Blocking IL-21 signaling ameliorates xenogeneic GVHD induced by human lymphocytes. Blood 2011; 119:619-28; PMID: 22077059; http://dx.doi.org/10.1182/ blood-2011-07-368027